Maintaining low HIV seroprevalence in populations of injecting drug users

D. C. Des Jarlais, H. Hagan, S. R. Friedman, Patricia Friedmann, D. Goldberg, M. Frischer, S. Green, K. Tunving, B. Ljungberg, A. Wodak, M. Ross, D. Purchase, M. E. Millson, T. Myers

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Objectives. - To describe prevention activities and risk behavior in cities where human immunodeficiency virus (HIV) was introduced into the local population of injecting drug users (IDUs), but where seroprevalence has nevertheless remained low (<5%) during at least 5 years. Design and Setting. - A literature search identified five such cities: Glasgow, Scotland; Lund, Sweden; Sydney, New South Wales, Australia; Tacoma, Wash; and Toronto, Ontario. Case histories were prepared for each city, including data on prevention activities and current levels of risk behavior among IDUs. Participants. - Injecting drug users recruited from both drug treatment and nontreatment settings in each city. Interventions. - A variety of HIV prevention activities for IDUs had been implemented in each of the five cities. Results. - There were three common prevention components present in all five cities: (1) implementation of prevention activities when HIV seroprevalence was still low, (2) provision of sterile injection equipment, and (3) community outreach to IDUs. Moderate levels of risk behavior continued with one third or more of the IDUs reporting recent unsafe injections. Conclusions. - In low-seroprevalence areas, it appears possible to severely limit transmission of HIV among populations of IDUs, despite continuing risk behavior among a substantial proportion of the population. Pending further studies, the common prevention components (beginning early, community outreach, and access to sterile injection equipment) should be implemented wherever populations of IDUs are at risk for rapid spread of HIV.

Original languageEnglish (US)
Pages (from-to)1226-1231
Number of pages6
JournalJournal of the American Medical Association
Volume274
Issue number15
StatePublished - 1995
Externally publishedYes

Fingerprint

Seroepidemiologic Studies
Drug Users
HIV
Risk-Taking
Population
Community-Institutional Relations
Injections
Equipment and Supplies
South Australia
New South Wales
Scotland
Ontario
Sweden
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Des Jarlais, D. C., Hagan, H., Friedman, S. R., Friedmann, P., Goldberg, D., Frischer, M., ... Myers, T. (1995). Maintaining low HIV seroprevalence in populations of injecting drug users. Journal of the American Medical Association, 274(15), 1226-1231.

Maintaining low HIV seroprevalence in populations of injecting drug users. / Des Jarlais, D. C.; Hagan, H.; Friedman, S. R.; Friedmann, Patricia; Goldberg, D.; Frischer, M.; Green, S.; Tunving, K.; Ljungberg, B.; Wodak, A.; Ross, M.; Purchase, D.; Millson, M. E.; Myers, T.

In: Journal of the American Medical Association, Vol. 274, No. 15, 1995, p. 1226-1231.

Research output: Contribution to journalArticle

Des Jarlais, DC, Hagan, H, Friedman, SR, Friedmann, P, Goldberg, D, Frischer, M, Green, S, Tunving, K, Ljungberg, B, Wodak, A, Ross, M, Purchase, D, Millson, ME & Myers, T 1995, 'Maintaining low HIV seroprevalence in populations of injecting drug users', Journal of the American Medical Association, vol. 274, no. 15, pp. 1226-1231.
Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M et al. Maintaining low HIV seroprevalence in populations of injecting drug users. Journal of the American Medical Association. 1995;274(15):1226-1231.
Des Jarlais, D. C. ; Hagan, H. ; Friedman, S. R. ; Friedmann, Patricia ; Goldberg, D. ; Frischer, M. ; Green, S. ; Tunving, K. ; Ljungberg, B. ; Wodak, A. ; Ross, M. ; Purchase, D. ; Millson, M. E. ; Myers, T. / Maintaining low HIV seroprevalence in populations of injecting drug users. In: Journal of the American Medical Association. 1995 ; Vol. 274, No. 15. pp. 1226-1231.
@article{964134a6bd4c4d7b91505c337915940e,
title = "Maintaining low HIV seroprevalence in populations of injecting drug users",
abstract = "Objectives. - To describe prevention activities and risk behavior in cities where human immunodeficiency virus (HIV) was introduced into the local population of injecting drug users (IDUs), but where seroprevalence has nevertheless remained low (<5{\%}) during at least 5 years. Design and Setting. - A literature search identified five such cities: Glasgow, Scotland; Lund, Sweden; Sydney, New South Wales, Australia; Tacoma, Wash; and Toronto, Ontario. Case histories were prepared for each city, including data on prevention activities and current levels of risk behavior among IDUs. Participants. - Injecting drug users recruited from both drug treatment and nontreatment settings in each city. Interventions. - A variety of HIV prevention activities for IDUs had been implemented in each of the five cities. Results. - There were three common prevention components present in all five cities: (1) implementation of prevention activities when HIV seroprevalence was still low, (2) provision of sterile injection equipment, and (3) community outreach to IDUs. Moderate levels of risk behavior continued with one third or more of the IDUs reporting recent unsafe injections. Conclusions. - In low-seroprevalence areas, it appears possible to severely limit transmission of HIV among populations of IDUs, despite continuing risk behavior among a substantial proportion of the population. Pending further studies, the common prevention components (beginning early, community outreach, and access to sterile injection equipment) should be implemented wherever populations of IDUs are at risk for rapid spread of HIV.",
author = "{Des Jarlais}, {D. C.} and H. Hagan and Friedman, {S. R.} and Patricia Friedmann and D. Goldberg and M. Frischer and S. Green and K. Tunving and B. Ljungberg and A. Wodak and M. Ross and D. Purchase and Millson, {M. E.} and T. Myers",
year = "1995",
language = "English (US)",
volume = "274",
pages = "1226--1231",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "15",

}

TY - JOUR

T1 - Maintaining low HIV seroprevalence in populations of injecting drug users

AU - Des Jarlais, D. C.

AU - Hagan, H.

AU - Friedman, S. R.

AU - Friedmann, Patricia

AU - Goldberg, D.

AU - Frischer, M.

AU - Green, S.

AU - Tunving, K.

AU - Ljungberg, B.

AU - Wodak, A.

AU - Ross, M.

AU - Purchase, D.

AU - Millson, M. E.

AU - Myers, T.

PY - 1995

Y1 - 1995

N2 - Objectives. - To describe prevention activities and risk behavior in cities where human immunodeficiency virus (HIV) was introduced into the local population of injecting drug users (IDUs), but where seroprevalence has nevertheless remained low (<5%) during at least 5 years. Design and Setting. - A literature search identified five such cities: Glasgow, Scotland; Lund, Sweden; Sydney, New South Wales, Australia; Tacoma, Wash; and Toronto, Ontario. Case histories were prepared for each city, including data on prevention activities and current levels of risk behavior among IDUs. Participants. - Injecting drug users recruited from both drug treatment and nontreatment settings in each city. Interventions. - A variety of HIV prevention activities for IDUs had been implemented in each of the five cities. Results. - There were three common prevention components present in all five cities: (1) implementation of prevention activities when HIV seroprevalence was still low, (2) provision of sterile injection equipment, and (3) community outreach to IDUs. Moderate levels of risk behavior continued with one third or more of the IDUs reporting recent unsafe injections. Conclusions. - In low-seroprevalence areas, it appears possible to severely limit transmission of HIV among populations of IDUs, despite continuing risk behavior among a substantial proportion of the population. Pending further studies, the common prevention components (beginning early, community outreach, and access to sterile injection equipment) should be implemented wherever populations of IDUs are at risk for rapid spread of HIV.

AB - Objectives. - To describe prevention activities and risk behavior in cities where human immunodeficiency virus (HIV) was introduced into the local population of injecting drug users (IDUs), but where seroprevalence has nevertheless remained low (<5%) during at least 5 years. Design and Setting. - A literature search identified five such cities: Glasgow, Scotland; Lund, Sweden; Sydney, New South Wales, Australia; Tacoma, Wash; and Toronto, Ontario. Case histories were prepared for each city, including data on prevention activities and current levels of risk behavior among IDUs. Participants. - Injecting drug users recruited from both drug treatment and nontreatment settings in each city. Interventions. - A variety of HIV prevention activities for IDUs had been implemented in each of the five cities. Results. - There were three common prevention components present in all five cities: (1) implementation of prevention activities when HIV seroprevalence was still low, (2) provision of sterile injection equipment, and (3) community outreach to IDUs. Moderate levels of risk behavior continued with one third or more of the IDUs reporting recent unsafe injections. Conclusions. - In low-seroprevalence areas, it appears possible to severely limit transmission of HIV among populations of IDUs, despite continuing risk behavior among a substantial proportion of the population. Pending further studies, the common prevention components (beginning early, community outreach, and access to sterile injection equipment) should be implemented wherever populations of IDUs are at risk for rapid spread of HIV.

UR - http://www.scopus.com/inward/record.url?scp=0028787806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028787806&partnerID=8YFLogxK

M3 - Article

C2 - 7563513

AN - SCOPUS:0028787806

VL - 274

SP - 1226

EP - 1231

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 15

ER -